Artemether-Lumefantrine Combination for Non-Comorbid Falciparum Malaria: A Clinico-Parasitological Efficacy Study

Chinelo K. Ezejiegu1, Angus N. Oli1*, Chinwendu N. Ezomike2, Christian C. Uba3, Uchenna C. Ogwaluonye1, Charles O. Esimone1
1Department of Biochemistry and Molecular Biology, Federal University Dutsinma, Katsina State, Nigeria
2Department of Chemistry, College of Education, Azare, Bauchi State, Nigeria


Corresponding Author: [email protected] ; Tel: +234-8056306927
Recieved Date: 01 October 2022; Accepted Date: 11 October 2022; Published Date: 01 November
Citation:
© 2022 Ezejiegu et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Visit for more related articles at  Tropical Journal of Natural Product Research



http://www.doi.org/10.26538/tjnpr/v6i10.26
Copyright:
© 2022 Ezejiegu et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Visit for more related articles at  Tropical Journal of Natural Product Research














ABSTRACT

With the emergence of chloroquine resistance, Artemisinin Combination Therapy use was advocated for by the WHO and this has been fully adopted by Nigeria for treating malaria due to P. falciparum infection. The present study focused on assessing the clinico-parasitological efficacy of Artemether-Lumefantrine, following the need to monitor the efficacy of ACTs as a tool for early detection of resistance. The WHO 2009 protocols for studying the efficacy of antimalarial agents were adopted. The study enrolled 75 adult patients living within Anambra state, diagnosed with falciparum malaria and met the inclusion criteria of the study. Patients were administered 6 doses of Artemether-Lumefantrine and monitored for 28days for any therapy failure or adverse events. Early treatment failure of 15.95% was recorded. Although ACPR, cure rate and parasite clearance were above 70% (76.8%, 97.10% and 80.4% respectively). The study also showed clearance of asexual stage (gametocytes) by day 3 of treatment. There was a satisfactory efficacy and safety of AL thus supporting the continued use of AL as the drug of choice for non-complicated malaria in the studied population.

Keywords: Artemisinin-Based-Combination therapy, Malaria, Artemether-lumefantrine,Antimalarial Drug, 
Back to Articles

ISSN: 2616-0684 (Print)
ISSN: 2616-0692 (Online)
DOI: 10.26538/tjnpr
Index Copernicus Value (ICV) for 2017: 59.83
Scopus citescore 0.3 (2020)

Indexing & Abstracting

citescore 0.3 (2020)

j-gate logo

International Innovative Journal Impact Factor

African Index Medicus

CAS

Index Copernicus International

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License

Crossref Content Registration logo

WorldCat Discovery Service

Geneva Foundation for Medical Education and Research